Novonix (NVX) Current Deferred Revenue (2020 - 2025)

Novonix (NVX) has reported Current Deferred Revenue for 6 consecutive years, with $146475.0 the latest figure, recorded in Q4 2025.

• Quarterly Current Deferred Revenue rose 16.2% year-over-year to $146475.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $146475.0 (up 16.2% YoY) and the FY2025 annual result came in at $146475.0, up 16.2% from the prior year.
• Current Deferred Revenue grew to $146475.0 in Q4 2025 per NVX's latest filing, from $126056.0 in the prior quarter.
• Over the last five years, Current Deferred Revenue for NVX reached as high as $324131.0 in Q2 2024 and fell as low as $2781.1 in Q2 2022.
• A 5-year average of $205382.6 and a median of $236587.8 in 2021 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2022 — Current Deferred Revenue sank 98.73% — and 2023, when it soared 9039.29%.
• Year by year, Current Deferred Revenue stood at $219001.7 in 2021, then soared by 30.24% to $285221.0 in 2022, then changed by 0.0% to $285221.0 in 2023, then sank by 55.8% to $126056.0 in 2024, then climbed by 16.2% to $146475.0 in 2025.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $146475.0, $126056.0, and $324131.0 for Q4 2025, Q4 2024, and Q2 2024 respectively.